ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: Compugen Ltd. (CGEN) Report Updated: Aug 25, 2014 | Print This Page

Get more stock ratings by Louis Navellier

Compugen Ltd. (CGEN)

Rating: Sell Volatility: Aggressive
Total Grade: D Industry: Life Sciences Tools & Services
Competitors: NEO, ILMN, AXDX, ENZ

Stock Analysis

Rating: Monthly View

A
B
C
D
F
August September October November December January February March April May June July

Rating: Weekly View

This Week: D down downgrade
Last Week: C same no change
Two Weeks Ago: C up downgrade
service keys

Compugen Ltd.© quotemedia

Company Profile

Compugen Ltd., a therapeutic product discovery company, focuses on the therapeutic proteins and monoclonal antibodies to address unmet needs in the fields of immunology and oncology. Its discovery efforts consist of in silico (by computer) product candidate prediction and selection followed by experimental validation. The company’s therapeutic proteins comprise CGEN-15001, a novel protein for the treatment of autoimmune disorders; CGEN-15021, a novel fusion protein to treat multiple sclerosis, rheumatoid arthritis, and other autoimmune diseases; CGEN-15091, a novel fusion protein for the treatment of multiple sclerosis and autoimmune diseases. Its monoclonal antibody target product candidates include CGEN-671, a drug for multiple epithelial tumors; CGEN-928, a drug for multiple myeloma; and CGEN-15001T, a novel B7/CD28 family member; and CGEN-15022 and CGEN-15092 for cancer immunotherapy. Compugen Ltd. was founded in 1993 and is headquartered in Tel Aviv, Israel.

Recent News: Compugen Ltd.